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Electrochemotherapy (ECT) has recently emerged as a treatment for cutaneous and subcutaneous lesions 
from different malignancies, including squamous cell carcinoma (SCC), with curative or palliative intent [1]. 
It  combines the delivery of electric  pulses into the lesions with the effect  of anticancer drugs  such as 
bleomycin and cisplatin; the increased cell membrane permeability following the electric pulse enhances 
drug  uptake  into  tumoral  cells  and  raises  the  cytotoxicity  of  these  intravenously  or  intralesionally 
administered molecules. With respect to surgery, radiotherapy and other standard treatments [2], ECT acts 
rapidly on multiple lesions with limited side effects and no functional impairment; moreover, repeated 
sessions can be performed to achieve or maintain the clinical response. 
We present an 80-year-old male admitted at our institution with multiple erythematous nodules, ranging 
from 0.5 to 1.5 cm in diameter, at the right fronto-parieto-occipital region (figure 1A). One month before he 
had undergone  the excision  of  an infiltrating squamous cell  carcinoma of  the vertex;  due to  its  large 
extension and infiltrating growth a cycle of radiotherapy immediately followed surgery but was interrupted 
for the appearance of multiple histologically confirmed secondary lesions surrounding the treated area. 
Due  to  the  number  and  extension  of  nodules,  standard  approaches  were  excluded;  we  therefore 
performed ECT. Treatment was carried out under mild general anaesthesia, with 15 mg/m2 intravenous 
bleomycin. Electrical pulses were generated and applied using the Cliniporator TM device (IGEA Ltd.) and 
type III hexagonal electrodes. A response was already observed at week 2 after treatment (figure 1B). At 
week  8,  a  relapse of  3  lesions  was  observed:  the  recurrences  appeared as  small  necrotic  ulcers  with 
erythematous and infiltrated borders, the largest diameter measuring 3.5 cm. Thus,  a second ECT was 
performed and a new complete regression was obtained; at week 4 the infiltration was no longer evident 
and only residual superficial ulcers covered by necrotic crusts were present. Unfortunately, two months 
after treatment the patient developed parotid gland and regional lymph node involvement and died 3 
months later of a systemic progression. 
Since  the  early  1990s,  clinical  and  preclinical  studies  have  been  conducted  on  ECT,  many  including 
cutaneous and mucosal SCC [2, 3]; but only recently has ECT entered clinical practice and its use in SCC 
remains limited. 
The most recent ECT prospective non-randomized trials [2, 4] included SCC patients: a good clinical activity 
was  reported,  with  no  significant  differences  in  response rates  according  to  nodule  size,  and  without 
relevant side effects.A recent paper by Landstrom et al. [5] described the results obtained in 6 cases of 
head and neck skin cancer (HNSC),  including 3 SCC:  in  4/6 cases,  tumour eradication with satisfactory 
cosmetic  results  was  obtained  after  only  one  ECT  session,  suggesting  the  alternative  role  of  ECT  in 
complicated skin cancers. In another study including 9 SCC [6], an 80% CR rate was achieved. The remaining 
3 patients achieved a PR, but the reduction in nodule size allowed for surgical excision, confirming the role 
of ECT also as a neoadjuvant treatment. In our patient, with the infeasibility of surgery and radiotherapy, 
ECT  represented  a  valuable  therapeutic  option;  in  fact,  with  this  relatively  simple  and  well-tolerated 
procedure, a satisfactory and prompted response was obtained. Another relevant point was the possibility 
of successfully retreating relapsed lesions, maintaining a good local control of the disease. However, ECT 
remains a local treatment, which does not prevent disease progression. ECT can be considered as a radical 
treatment in cases with limited disease with a more indolent behaviour,  where surgery would cause a 
cosmetic and functional impairment.  
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Figure 1. Recurrences of scalp squamous cell carcinoma at right fronto-parieto-occipital region before (A) 
and 2 weeks after (B) 1st ECT.
